|
|
|
|
| LEADER |
04937nmm a2200349 u 4500 |
| 001 |
EB002152769 |
| 003 |
EBX01000000000000001290895 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230403 ||| eng |
| 020 |
|
|
|a 9783031231759
|
| 100 |
1 |
|
|a Vermorken, Jan B.
|e [editor]
|
| 245 |
0 |
0 |
|a Critical Issues in Head and Neck Oncology
|h Elektronische Ressource
|b Key Concepts from the Eighth THNO Meeting
|c edited by Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O'Sullivan
|
| 250 |
|
|
|a 1st ed. 2023
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2023, 2023
|
| 300 |
|
|
|a IX, 365 p. 65 illus., 58 illus. in color
|b online resource
|
| 505 |
0 |
|
|a The gut microbiota and anticancer immunotherapy, Laurence Zitvogel -- The bidirectional communication between tumor cells and other components of the tumor microenvironment, Phil Sloan -- Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this, Kirsten Lauber -- DNA repair mechanisms as a new target in head and neck cancer, Kevin Harrington -- How to standardize molecular profiling programs for routine patient care, Ingeborg Tinhofer -- Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer, Christophe Le Tourneau -- Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches, Ben O’Leary -- Clinical cases, Jean Pascal Machiels -- Updates from the European Head & Neck Society (EHNS), Wojciech Golusinski (President of EHNS) Section 2: Primary disease Piero Nicolai --
|
| 505 |
0 |
|
|a Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neckcancer, Brian O’Sullivan -- From photon to proton: what’s in it for head and neck cancer patients?, Volker Budach -- Lessons learned from RTOG 1016 and DE-ESCALaTE: what’s next?, Hisham Mehanna.-Treatment intensification in LA-SCCHN: what are the options and for who?, Jan Vermorken -- Immune checkpoint inhibitors in the curative setting: preclinical and clinical data, Jean-Pascal Machiels -- Carcinoma of unknown primary: diagnostics and the potential of transoral surgery, René Leemans -- Clinical cases, Volker Budach -- Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?, Petr Szturz -- Patterns of response to immune oncology drugs: how relevant are they in SCCHN?, Amanda Psyrri -- The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN, Daan Nevens --
|
| 505 |
0 |
|
|a Updates from the EORTC Head and Neck Cancer Group (HNCG), Jean-Pascal Machiels (Chair of EORTC-HNCG) -- Real world evidence in head and neck cancer, Anil D’Cruz (UICC president -- Pathology driven treatment of skull base tumors, Piero Nicolai -- Modern day reconstruction of facial bones, Sat Parmar -- Targeting molecular/minimal residual disease using novel technologies and clinical trials design, Lillian Siu -- New developments in surgery for malignant salivary gland tumors, Jeroen Meulemans -- New systemic therapies in salivary gland cancer, Ethan Argiris. Exercise and nutrition interventions in head and neck cancer, Paolo Bossi -- Telehealth intervention in head and neck cancer patients: a promise?, Irma Verdonck-de Leeuw
|
| 653 |
|
|
|a Radiology
|
| 653 |
|
|
|a Cancer Therapy
|
| 653 |
|
|
|a Cancer / Treatment
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Budach, Volker
|e [editor]
|
| 700 |
1 |
|
|a Leemans, C. René
|e [editor]
|
| 700 |
1 |
|
|a Machiels, Jean-Pascal
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 028 |
5 |
0 |
|a 10.1007/978-3-031-23175-9
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-031-23175-9?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a This is an open access book. With a wealth of exciting data emerging in this rapidly evolving field this book will review the state-of-the-art knowledge with emphasis on multidisciplinary decision and management of head and neck cancer. The book provides significant detail on a wide range of topics including: the role of new targets for treatment, immunotherapy, resistance mechanisms, standardizing molecular profiling programs, and new methods to guide therapeutic approaches. In addition different disease situations are addressed including different treatment approaches in primary disease and in recurrent and/or metastatic disease as well as new developments in pathology, surgery and reconstruction techniques, new systemic therapies in salivary gland cancer, and supportive care and follow-up. All disciplines involved in the treatment of head & neck cancer are covered with a focus on translation into daily practice. The 8th-THNO is designed for medical oncologists, head and neck surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment of patients with head and neck cancer
|